Mirati Therapeutics, Inc. (MRTX): Price and Financial Metrics

Mirati Therapeutics, Inc. (MRTX): $58.70

0.10 (-0.17%)

POWR Rating

Component Grades








Add MRTX to Watchlist
Sign Up

Industry: Biotech




#304 of 359

in industry

MRTX Price/Volume Stats

Current price $58.70 52-week high $64.41
Prev. close $58.80 52-week low $27.30
Day low $58.54 Volume 20,994,400
Day high $58.99 Avg. volume 2,758,857
50-day MA $57.69 Dividend yield N/A
200-day MA $45.47 Market Cap 4.12B

MRTX Stock Price Chart Interactive Chart >

Mirati Therapeutics, Inc. (MRTX) Company Bio

Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. The company was founded in 1995 and is based in San Diego, California.

MRTX Latest News Stream

Event/Time News Detail
Loading, please wait...

MRTX Latest Social Stream

Loading social stream, please wait...

View Full MRTX Social Stream

Latest MRTX News From Around the Web

Below are the latest news stories about MIRATI THERAPEUTICS INC that investors may wish to consider to help them evaluate MRTX as an investment opportunity.

FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

Yahoo | December 27, 2023

Mirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 Shares

On December 18, 2023, Jamie Christensen, EVP & Chief Scientific Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), executed a sale of 2,387 shares in the company.

Yahoo | December 20, 2023

Insider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)

In a recent transaction on December 13, 2023, Benjamin Hickey, the Executive Vice President and Chief Commercial Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), sold 2,220 shares of the company.

Yahoo | December 15, 2023

Billionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Charges

(Bloomberg) -- Joe Lewis, the British billionaire behind one of the world’s biggest investing fortunes, continues to buy and sell stocks at the center of US insider-trading allegations against him.Most Read from BloombergJPMorgan Is in a Fight Over Its Client’s Lost $50 Million FortuneGoldman Trader Paid $100 Million Since 2020 Is Stepping DownArgentina’s Milei Devalues Peso by 54% in First Batch of Shock MeasuresNetflix Posts Viewer Data on Every Show, Film for First TimeRaimondo Vows ‘Stronges

Yahoo | December 12, 2023

3 Resilient Stocks with Massive Potential to Boost Your Wealth

These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life.

Rich Duprey on InvestorPlace | November 26, 2023

Read More 'MRTX' Stories Here

MRTX Price Returns

1-mo N/A
3-mo -0.17%
6-mo 5.42%
1-year 38.12%
3-year -62.12%
5-year -7.22%
YTD -0.09%
2023 29.66%
2022 -69.11%
2021 -33.21%
2020 70.45%
2019 203.77%

Continue Researching MRTX

Want to see what other sources are saying about Mirati Therapeutics Inc's financials and stock price? Try the links below:

Mirati Therapeutics Inc (MRTX) Stock Price | Nasdaq
Mirati Therapeutics Inc (MRTX) Stock Quote, History and News - Yahoo Finance
Mirati Therapeutics Inc (MRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!